issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
following significant Board’s resolutions:- 1. Approved the acquisition by the Company and its wholly ordinary shares of Aesthetic Zecret Co., Ltd. (“At-Ze”) from its ex-shareholders and will increase capital
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Deduct Minority interest - - Net tangible assets (NTA) 604.68 (0.22) Plus Capital increase from ex-shareholder :At-Ze prior to share sale and purchase date* - 30.00 Net tangible assets (NTA)-adjusted
Intangible assets deduct 11.53 0.54 Deduct Total liabilities 315.37 157.34 Deduct Minority interest - - Net tangible assets (NTA) 604.68 (0.22) Plus Capital increase from ex-shareholder :At-Ze prior to share
690.75 million baht or an increase of 5.67 percent (2Q2019: 653.67 million baht). The profit before finance costs, tax, depreciation and amortization of 620.54 million baht or increased by 15.56 percent
will focus on more premium products to increase profitability, and more mass products to increase sales volume, both in the fruit juice category as well as other categories, which will also help reach
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
Baht 0.40 and 0.83 respectively. The decreased loss is due to the major transactions as follow: 1. The increase of net earned premium in this quarter compared to the same period of last year in the
runs the drug business and a small hospital by Modern Company without loan Adjust, increase and decrease, an additional 0.25% discount rate will be valued between 278.25-312.67 million Baht 7. Criteria